Monogram Orthopaedics offering is now closed and is no longer accepting investments.
INVEST IN MONOGRAM ORTHOPAEDICS TODAY!
Future of Joint Replacement
$22,127,091.43 Raised
Monogram has not yet applied for or obtained FDA approval for our novel Monogram products and sales of novel Monogram products may not commence until approval is received.
Reasons to Invest
- World-class team with a track record of execution: led by a team of experts in robotics and medical technology, and advised by surgeon consultants from institutions such as Columbia and Icahn School of Medicine.
- First revenues in 2021 & new product launches: we have generated our first revenue in 2021 and expect to launch our first-gen implants during the first half of 2022.
- Already raised $16.7M from 6,793 investors: We have been through 3 successful financing rounds and continue to execute.
- Established product-market fit: the leading orthopedic robot on the market (technology from a startup acquired in 2013) outsells its next largest competitor over 12-to-1 with an 87% share. We understand its limitations and have the team to build the future of robotics.
- Novel technology for massive growing market: The joint replacement market is approximately $19.6BN, with over 1 million knee replacements per year. We believe we will be one of the first to market with our technology and fourteen patent filings.
- Winner of award from National Science Foundation (NSF): Recipient of SBIR Phase I award for "Development of a tracking system for computer-assisted surgery."
Overview
Our mission is to make orthopedics personal
Monogram Orthopedics will use the latest in robotic, AI, and 3-D printing technologies to make orthopedic care personal. Monogram will try and make every design and development decision by focusing on what we think will most benefit patients and improve clinical outcomes (note: this is based on management opinion and has not been demonstrated in live patients).
Four companies currently dominate the multi-billion dollar joint reconstruction market with an 82% combined share in knees (source). Many companies fail to penetrate this market, as many believe change isn’t possible.
*above image is computer generated and not yet available for commercial sales
With what we believe to be innovative robotic and implant technologies, we will try to improve the accuracy of implant placement, and we hope thereby improve patient outcomes at a lower cost (note: this is based on management opinion and has not been demonstrated in live patients). Our priority is clinical benefits for patients and true patient satisfaction. We believe patients and surgeons alike deserve better. Monogram's goal is to try and lead what we believe to be the future of joint reconstruction.
(Source 1)
The Problem
One size fits none approach leaves patients behind
Up to 10% of all knee and 15% of hip replacements fail annually (source). These failures are in part because the technology is inherently inefficient and subject to surgeon error. Joint replacement technology has, in many ways, remained the same for 40 to 50 years. Often crude and finicky instruments like saws and jigs are used to prepare the bone for geometric and rigid generic implants that don't accurately fit. Insertions are often eyeballed and subject to proper surgeon execution. Management believes we may be able to design the Monogram workflow for efficiency and accuracy by leveraging the technical manufacturer specifications of our robot arm.
Furthermore, four large companies dominate the market, leaving little room for innovation. This consolidation hurts patients and surgeons by limiting patient options and slowing the pace of technological progress.
Traditional surgeries are also highly inefficient, with underutilized instruments and unused implants that add to the treatment burden. Monogram aims to reduce the required instrumentation needed to perform joint replacement procedures and streamline inventory requirements. We believe this will be especially beneficial as the market shifts to Ambulatory Surgery Centers.
Our primary focus is the wellbeing of our future patients. Revisions and failures are serious and far too frequent. We plan our cases for execution with a state-of-the-art surgical robot. We believe the combined improvements to the robot and implants could potentially benefit patient outcomes and mitigate risk - this is based on management opinion and has not been demonstrated in live patients.
Patients and surgeons need more comprehensive, clinical focused solutions that truly fit their needs.
The Solution
The next-gen 3D implant solution
We design implants for active patients that want to restore their quality of life. Management believes our integrated solution may eliminate the cost and improve efficiency in the operating room by reducing instrumentation and optimizing the cut path execution.
We have optimized our next-generation joint replacement solution with a state-of-the-art robot.
Monogram is committed to developing patient-optimized orthopedic implants, inserted with a surgical robot for unparalleled precision. Our navigated surgical robot relies on a CT-based pre-operative plan and has more reach (approximately 4.2 feet), with 7-degrees of freedom. (source, pg 5)
(Source 1)
Our fully-personalized system breaks the barriers of traditional, cemented implant procedures that rely on manual instrumentation. While the underlying technologies are highly sophisticated and complex, the workflow remains straightforward and capital efficient.
GIF 1
GIF 2
GIF 3
GIF 4
GIF 5
“By failing to plan, you are planning to fail.” – Benjamin Franklin
The Market
A $19.6 billion joint replacement market in need of innovative disruption
The joint replacement market is currently at $19.6BN (source) with hip and knee replacements being the most common. The knee replacements market is $8.7 billion (source). Despite the market's significant size, innovation has plateaued because just four large companies dominate. Monogram's first addressable market will be total knee replacements, with almost 1 million knee replacements performed in the United States annually (source). Some market estimates project there will be nearly 3.5 million annual Total Knee Replacement procedures by the year 2030 (source)
(Source 1)
By 2027, approximately 50% of all knee procedures will be robotic, up from 11% in 2019 (source). In the United States, we currently cement 92% of knees versus only 3% of hips. We believe that surgeons prefer uncemented or "press-fit" implants (source) and management believes press-fit knee adoption represents one of the most significant growth opportunities in orthopedics. Monogram is developing a next generation uncemented knee designed that we expect will benefit from these macro trends.
A significant driver of press-fit implant utilization (the type of implant Monogram is developing) is patient demographics. Improved low wear plastics make joint replacements more suitable for younger patients. In particular, patients less than 65 years of age represent the fastest-growing population of TKR recipients, expected to account for more than 50% of knee replacement procedures by the year 2030 (source). We are designing the Monogram implants to meet the demands of younger active patients.
Another tectonic market shift that we see driving the adoption of technologies is the growing outpatient trend to Ambulatory Surgery Centers. In January 2018, the Centers for Medicare & Medicaid Services (CMS) removed knee replacement procedures from the inpatient-only list, allowing procedures to be conducted on an outpatient basis.
Across the country, the average cost for an inpatient knee replacement is $30,249, compared to $19,002 in the outpatient setting (source)- we believe these cost savings will drive significant volumes away from high volume hospitals.
Our Traction
Significant capital raised, fourteen patents filed, and trusted surgeon advisors to support product-market fit
Monogram has raised $16.7 million with 6,793 trusted shareholders. We are actively deploying this capital to develop our novel orthopedic technologies and the operating and sales infrastructure needed to support their distribution. Monogram has recruited five practicing surgeons to support our development and validation efforts and provide practical user input. We aim for our products to be suitable for both the surgeon user and our patients.
To date, we have signed contracts with two distributors that will market Monogram to select geographies. We expect to generate revenue from licensed implants in 2021. We have a newly completed 350 square foot Monogram cadaver lab based in Austin, Texas, along with a team of 16 full-time employees. We have filed fourteen patents related to our proprietary technologies, as well as a Freedom-to-Operate (FTO) search for Monogram's knee design with a robotic surgical approach.
Our internal cadaver lab allows our engineers to develop and validate many of our products more efficiently and economically. In parallel, the lab supports our sales channels by allowing our team to demonstrate the product pipeline and share the vision with distributors and surgeons with live cadaveric surgeries before FDA approval.
*future events are anticipated based on full funding of the company in this offering or from other sources, and there is no guarantee the company will be able to meet those future milestones
What We Do
Implants that perfectly match every patient
At Monogram, we believe that there is a better, less-invasive way to treat patients. We combine 3D printing and robotics with CT-based pre-operative planning to enable mass personalization of the next generation of orthopedic implants.
Implant Design, Reimagined
The process starts with a CT scan, which is the starting point for personalization. From the CT scan, we can create an accurate patient-specific 3D models of the bony anatomy. By building a customized implant for every patient, we believe we may be able to more fully restore anatomical function and mitigate clinical risks (note: this has not been demonstrated in live patients). We believe bone conserving highly stable press-fit implants that rely on natural biologic fixation will improve patient outcomes and usher in the future of orthopedics (note: this is based on management opinion and has not been demonstrated in live patients).
GIF 6
3D Printed Implants
Unlike conventional, expensive, labor-intensive manufacturing, Monogram will deliver highly personalized implants efficiently at scale by leveraging state-of-the-art manufacturing methods and 3D printing.
All Monogram implants will undergo rigorous validations and testing to ensure the highest industry quality standards. Monogram has conducted extensive mechanical strength testing that tries to simulate the rigorous ISO strength testing standards mandated by the FDA (we have not yet submitted our implants for the ISO strength tests mandated by the FDA and we can make no assurances that our implants will pass such testing). Our implants will be a biocompatible medical-grade titanium alloy (Ti64) with a chemical composition corresponding to ISO 5832-3, ASTM F1472, and ASTM B348.
GIF 7
Robotic Milling Cavity Technology
Monogram takes surgical robotics to the next level. There are currently no CT-based, navigated robots that actively execute bone cuts without user-initiated movements. Monogram aims to be the first company to release such a robot.
Our goal is to combine groundbreaking software with world-class hardware, delivering an integrated robotic system that addresses major clinical concerns today - cost, time, and a lack of efficient control.
GIF 8
The Business Model
Goal to Lower cost and try to improve accuracy and efficiency
We are developing the implant and robotics in parallel, but we plan to de-risk the commercialization with discrete FDA submissions. We have entered into a distribution agreement for an FDA approved total knee system, specific components of which we intend to integrate into our novel knee system for future release. As part of this agreement, we recruited the Senior Director of US Sales from the manufacturer to support early sales efforts.
Monogram intends to secure distribution relationships for these existing products before releasing our novel products as a Phase I release.
Monogram has not yet applied for or obtained FDA approval for our novel Monogram products and sales of novel Monogram products may not commence until approval is received.
In the second phase, Phase II, we intend to commercialize our patient-specific implants inserted manually (the "Gen 2" implant) as a discrete FDA submission. We hope to drive sales through the distribution channels established during the first phase, Phase I. In Phase III, we will release our surgical robot.
Monogram will have two primary revenue streams; a revenue stream from the sale of capital equipment and a revenue stream from our consumable products' sale. We expect to price our implants like the national ASP, and we will undercut competitive pricing for our capital equipment.
In the future, we intend to develop applications for additional clinical applications, including partial knees and hips, and we are investigating applications for shoulders, spine, and extremities.
How We Are Different
A fully integrated medical solution never seen in the market before
The Monogram management team sees a clear growth opportunity for an efficient and strategically priced navigated robotic surgical system that relies on advanced imaging like a CT-scan. We will design the Monogram implants and robotic system to have a good product-market fit for the growing demographic of patients age 64 and younger.
The current market consolidation also presents opportunities for Monogram. The size and operational complexity of our large competitors, with so many stakeholders and product lines, can make it difficult for them to advance disruptive innovations efficiently. Monogram sees a greenfield opportunity for a surgical robot that uses advanced imaging to actively and efficiently mill cavities for a perfect fit with 3D-designed implants. We believe we are on track for it to be the first of its kind in the market if we are successful.
In our testing conducted with our research partners, our implants appear to outperform leading generic equivalents by, in some variations, a considerable margin. We think we can design more stable bone conserving implants that rely on natural biologic fixation through an innovative design approach, and we think we can leverage the high accuracy manufacturer specifications of the robotic arm for accurate bone preparation and customization of the implant design and surgical plan to the specific patient. Personalization also minimizes the inventory and instrumentation, which eases the burden on hospitals and ASCs.
In summary, we provide a fully integrated, personalized orthopedic solution that combines custom bone preparation with optimized 3D printed implants that has never been done before. From the trend to ASCs to a younger patient demographic to increased robotic utilization, the underlying market dynamics all bode favorably.
The Vision
Commercialize a differentiated surgical robot for multiple orthopedic applications
The total orthopaedic market is over $53BN annually. Our initial focus is total knee replacements followed by partial knee and hip replacements - we are actively investigating shoulders, ankles, and spine. We expect to generate revenue in 2021.
Our vision is to improve the standard of care in orthopedics with personalized technology solutions. With a differentiated, navigated surgical robot that prepares the bone for clinically differentiated press-fit orthopedic implants, we will be able to make implants more stable that preserve the bone and rely on natural biologic fixation.
Monogram has executed two distribution agreements thus far. We expect to generate revenue in 2021, and we anticipate continuing to grow our sales network as we gain traction. We will leverage our dedicated cadaver lab, housed in our 4,000 square foot Austin facility, to demo our product pipeline to continue to build our distributor and surgeon relationships.
OUR LEADERSHIP
Led by surgeons and Medtech executives with engineering and finance expertise
Our founder and Chief Medical Officer, Dr. Douglas Unis, is a board-certified attending orthopedic surgeon for the Mount Sinai Health System. Dr. Unis, along with Caltech graduate and CEO - Benjamin Sexson, CFA, lead a team of experts in surgical robots and implant design. Our VP of Engineering is Kamran Shamaei, Ph.D., who worked with Think Surgical Inc. on the TSolution One Robot and supported the development of Monarch robots at Auris Health Inc. Chris Scifert, Ph.D., the former Director of Engineering for Orchid Orthopedic Solutions Design, one of the largest manufacturers of implants globally, is running the development of our implants and instruments.
Monogram has recruited five practicing surgeons to support our development and validation efforts and provide practical user input. These surgeons include doctors from The Orthopedic Specialty Center of Northern California, Orthopaedic Specialists of Austin and Columbia University.
Monogram currently employs 16 full-time employees and is actively contracting with four consulting firms with significant subject matter expertise.
Why Invest
Take medical robotics to the next level
The reasons to invest are straightforward; we have a proprietary technology for products that don't currently exist for a large and growing $19.6BN joint replacement market. We have protected our products with multiple IP filings that we know have a product-market fit because the only similar technology on the market has an 87% market share. While we have ambitious goals, we have successfully raised $16.7M to date and have assembled a differentiated team with the experience needed to execute. We believe we will be early to market with a solution with the potential to change the standard of care in orthopaedics.
Many companies are trying various solutions to compete - imageless registration, small footprints, portability, and cost. We think they are overthinking the proven solution and will struggle with adoption. We believe that the market desperately needs a viable alternative and none currently exists.
By investing in Monogram, you will be supporting an experienced team to develop the future of orthopedics, which we believe is patient optimized 3D printed implants designed for high accuracy robotic placement. With our fourteen patents pending, a leadership team of experts in medical and surgical technology, and a highly differentiated solution fit for the growing $19.6BN joint replacement market, we can minimize surgical risks and restore patients to their active lifestyles.
We hope you will join the adventure and invest in the future of orthopedics!
Monogram has not yet applied for or obtained FDA approval for our novel Monogram products and sales of novel Monogram products may not commence until approval is received.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
ABOUT
HEADQUARTERS
3913 Todd Lane
Austin, TX 78744
WEBSITE
View Site
Monogram is a medical technology company ushering in the future of joint reconstruction. Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms. We are designing our state-of-the-art surgical robot with the aim of mitigating the risks of poor placement, fracture, and subsidence to give surgeons confidence that they can install implants that fit every patient - perfectly.
TERMS
Monogram Orthopaedics
Overview
PRICE PER SHARE
$7.52
DEADLINE
Feb 19, 2022
VALUATION
$89.92M
AMOUNT RAISED
$22,127,091.43
Breakdown
MIN INVESTMENT
$250.80
MAX INVESTMENT
$34,863,105
MIN NUMBER OF SHARES OFFERED
1,329
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
Series B Preferred Stock
MAX NUMBER OF SHARES OFFERED
4,636,051
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Monogram Orthopedics, Inc, |
Corporate Address | : | 3913 Todd Lane, Austin, TX 78744 |
Offering Minimum | : | $0.00 |
Offering Maximum | : | $34,863,105.00 |
Minimum Investment Amount(per investor) | : | $250.80 |
Terms
Offering Type | : | Equity |
Security Name | : | Series B Preferred Stock |
Minimum Number of Shares Offered | : | 0 |
Maximum Number of Shares Offered | : | 4,636,051 |
Price per Share | : | $7.52 |
Pre-Money Valuation | : | $89,919,986.40 |
ALL UPDATES
11.10.22
Don’t Miss Our Live Upcoming Webinar and Q&A!
We invite you to join us for our upcoming Monogram investor webinar on November 16th at 2:00 PM EST!
This will be a great opportunity for investors and followers to hear from our founders Ben Sexson and Doug Unis. Ben and Doug will talk about what makes our precision surgical robots so unlike anything else on the market today, our FDA-approved personalized knee implants, the potential for an IPO in the near future, and more.
Be sure to stick around for an exclusive Q&A at the end.
We’re limiting the number of participants, so reserve your spot as soon as you can. We look forward to meeting you!
Save Your Spot here: https://www.monogramorthopedics.com/webinar
11.02.22
Monogram Receives NASDAQ Approval Reserving Ticker Symbol
Monogram Orthopaedics Inc. (monogramorthopedics.com) has received notification from NASDAQ's symbol reservation department stating, "Your request to reserve the ticker symbol "MGRM" for Monogram Orthopaedics Inc has been approved and will be reserved for you for twenty-four months."
Investors can identify securities listed on the New York Stock Exchange, the American Stock Exchange, or the NASDAQ system by a unique stock symbol or ticker symbol. The stock ticker symbol appears on the "ticker tape" that scrolls across the bottom of most financial news programs whenever the stock trades.
Benjamin Sexson, CEO, stated: "Getting a symbol reserved for trading is a meaningful milestone for Monogram. We will continue to work to meet additional corporate governance and other requirements for listing, knowing that we have our ticker symbol reservation approved."
Monogram is continuing its efforts to prepare to become a publicly traded company. Management believes that given its crowdfunded capital structure and product pipeline, there could be several benefits to becoming a publicly traded company.
The Company anticipates that its current Series-C round will be the last raise before its go-public round. Learn more at the company website: monogramorthopedics.com
02.19.22
My Final Thanks
Hello Monogram Community!
Wow, what a whirlwind. Our StartEngine raise has been such an incredible success so far. We’ve funded over $22 million from over 13,000 investors!
That’s why I wanted to express my sincerest gratitude to all of the investors who have supported us.
Now, our campaign is closing in a few hours. I'd like to invite you to make your first investment or purchase additional stock in our transformative orthopedic technology.
Let's bring this new tech to the world! Join us now and invest now before this investment round ends tonight!
Sincerely,
Ben Sexson
CEO of Monogram
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the Offering Circular and Risks related to this offering link. In addition as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.18.22
We've Raised $22 Million - Final Hours to Invest!
We made it to $22M and now it's time to set our sights on new heights.
So, we'd like to share more on how Monogram aims to improve its revenue for the long term. It's all about exceeding patient expectations since they determine the overall success and value of healthcare.
One in five knee replacement patients are not satisfied with the placements of their implants. And 36% of TKA (total knee arthroplasty) patients would have avoided surgery altogether if they anticipated the less than stellar results.
We’re here to change that.
Navigated robots, cutting systems, and navigation consumables are just a glimpse of the upcoming revolutionary solutions from the Monogram team.
These are exciting times for the joint replacement industry professionals and patients.
Don’t miss your chance to get in on the joint reconstruction revolution! This investment opportunity ends today!
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the Offering Circular and Risks related to this offering link. In addition as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.18.22
All-Day Monogram Webinars + $21M Milestone
We officially hit $21 million raised! I can’t believe how quickly this investment round has flown by. Today is closing day and this is your final chance to invest in Monogram’s 3D-printed joint implants and advanced surgical robotics.
We’re closing out this campaign with a bang. Our first-ever live surgery was a huge hit with thousands of live viewers and we’ve already raised over $21 million from 12,700+ investors!
But I know that you probably still have questions.
That’s why we’re running live webinars all day long. Sign up at any time and take advantage of this final opportunity to ask all of your investing inquiries.
Save your spot here or make your final Monogram investment on StartEngine before the day’s end.
Talk to you soon,
Ben Sexson
CEO of Monogram
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the Offering Circular and Risks related to this offering link. In addition as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.18.22
Monogram’s Raise Ends TODAY
Investors, today is the LAST day in Monogram’s StartEngine raise!
If you haven’t already invested or are thinking about purchasing even more Monogram shares, here are some reasons to invest.
Monogram Milestones:
Raised over $20 million in current round alone with over 12,000 investors
Generated over $600,000 in 2021 with our first product launch and plan to launch our first-gen implants this year
Won the SBIR Phase I award of $265,000 from the National Science Foundation
Already filed 14 patent applications
Team comprised of world-class experts in robotics and medical technology
Pioneering novel tech in a $20 billion joint replacement market with over 1 million annual knee replacements
You can still get in on the ground floor and join us on our mission to upgrade the standard of orthopedic technology.
Don’t miss this final chance to become a part-owner in Monogram.
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the Offering Circular and Risks related to this offering link. In addition as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.18.22
We've Reached $20M Raised + Final Day to Invest!
Monogram Orthopedics supporters,
We reached $20 million on StartEngine—that means a lot for our plans to reimagine orthopedic practices.
Did you know that there are only four companies that dominate the billion-dollar joint reconstruction market?
As a result of stagnant innovation, up to 10 percent of knee replacements and 15 percent of hip replacements fail every year due to a poor fit. There should never be a one-size-fits-all when it comes down to joint replacement surgery, and it's time to replace the outdated concept.
Through advanced robotics, Monogram is aiming to equip healthcare specialists with the capabilities of achieving pinpoint accuracy with every implant.
Monogram’s StartEngine round is closing TODAY. Don’t miss this chance to get in.
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the Offering Circular and Risks related to this offering link. In addition as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.18.22
$19M Raised + One Day Left to Invest!
Monogram Orthopedics supporters,
Monogram has raised $19M to date, and it’s a major step in the right direction. You can still join over 11,500 investors before our round closes on 2/18.
With funding for the efforts of leading experts in robotics and medical technology, we believe we are opening doors to brave new territories and breakthroughs.
Yes, it is a big deal, and we thought it would be great to fill you in on the details.
With your faith and trust in Monogram, we believe we can shape the course of history—optimizing the outcomes for over a million knee surgeries per year.
Through our innovation, our hope is that individuals will receive ideal medical support for joint replacement needs—no more ineffective standard solutions. Join us today.
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the Offering Circular and Risks related to this offering link. In addition as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.16.22
Monogram Receives New Cantilevered Carts!
Monogram Orthopedics supporters,
We thought it would be fun to bring you behind the scenes for the delivery of our second-generation cantilevered robot carts. A priority of our system design is collaboration, and the robot, surgeon, and surgical staff must work together seamlessly. We want a robot that supports the user's needs without a sense of the robot overwhelming the working volume.
In addition to our robot's incredible 51 inches of reach, we have angled the base and optimized the cutting tool mounting configuration to further expand the surgical working volume. It is important that users have 360-degree access to the surgical table.
The cart needed to be right next to the surgical table in early versions of our design. We enhanced the design to create space on all sides of the surgical table.
The robot cart won’t need to be pressed right up against the surgical table with the Monogram system. We have made significant efforts to enhance the surgeon experience while using our system.
We hope you join our live product reveal to see our robot cart in action! Please register now!
Wednesday, February 16th, 2022 @ 3 PM CST
Register: https://lnkd.in/eJCdKfQx
Kind regards,
Ben
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
02.15.22
Will you join us?
Monogram Orthopedics supporters,
On Wednesday, February 16th at 3 PM EST, Monogram is going live with what will be one of the most groundbreaking events for our company and maybe the entire industry.
During the livestream we will demo a navigated active sagittal cutter, which is currently the first product of its kind on the market.
Despite running a public-facing crowdfunding campaign, we have been relatively discrete regarding details of technical progress to the public. Some industry experts have thought some of our ambitions impossible. But now, this is your chance to see us in action. In fact, some of the most prominent players in our market representing over $150 billion of market value, numerous orthopedic surgeons, and many industry insiders have already reserved their spots. Are we just developing a solution in search of a problem, or have we identified a meaningful market opportunity?
We believe the industry attendance numbers speak for themselves.
In preparation for this exciting event, we’ve been working in stealth, including filing 14 patents and developing at an incredibly aggressive pace. Now, we can’t wait to show the world what we’ve been working on and how far we’ve come.
Join our Monogram Live Product Reveal on Wednesday, February 16th at 3 PM CST.
Reserve your seat here.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
REWARDS
$5,000
5% Bonus Shares
Invest $5,000 and receive 5% Bonus Shares on your investment
$10,000
10% Bonus Shares
Invest $10,000 and receive 10% Bonus Shares on your investment
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
